TY - JOUR
AU1 - Gueta, I.
AU2 - Loebstein, R.
AU3 - Markovits, N.
AU4 - Kamari, Y.
AU5 - Halkin, H.
AU6 - Livni, G.
AU7 - Yarden-Bilavsky, H.
AB - Purpose The purpose of this study is to determine the rate of tients treated with voriconazole are at increased risk for QTcP, QTcP and associated risk factors in patients treated with especially in the presence of baseline QTc ≥ 450 msec and low voriconazole. serum potassium levels. Methods We conducted a retrospective chart review of all . . patients treated with voriconazole in a large tertiary center Keywords Voriconazole QT prolongation Adverse . . between 2009 and 2015, using paired comparison of QTc effects Torsadedepointes Safety intervals on and off voriconazole treatment, adjusted for co- morbidities, electrolyte abnormalities, and concurrent medications. Background Results Fifty-four patients were included, of whom 53 were diagnosed with oncologic/hemato-oncologic disease. Mean Voriconazoleisapotentantifungalagentmainlyusedinimmune- QTc during voriconazole therapy (448.0 ± 52.9 msec) was compromised hemato-oncologic patients suffering from inva- significantly longer compared to QTc off voriconazole sive aspergillosis or candida infections [1]. Among the various (421.8 ± 42.2 msec; p = 0.002). QTcP ≥30 msec and ≥60 msec adverse events that have been associated with voriconazole, was demonstrated in 43% (23 patients) and 28% (15 patients), corrected QT interval prolongation (QTcP) is the most respectively. Multivariate analysis showed that QTcP was sig- concerning given its propensity 
TI - Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors
JF - European Journal of Clinical Pharmacology
DO - 10.1007/s00228-017-2284-5
DA - 2017-06-17
UR - https://www.deepdyve.com/lp/springer-journals/voriconazole-induced-qt-prolongation-among-hemato-oncologic-patients-F0JH7Ek0m0
SP - 1181
EP - 1185
VL - 73
IS - 9
DP - DeepDyve
ER -